Lifastuzumab vedotin

DB15400Investigational

Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).

Mechanism: Pharmacologically active on Sodium-dependent phosphate transport protein 2B
Curator reviewed
Code names: DNIB-0600A · NAPI3B · RG-7599

Resolves to

Compound

UNII7IUT83FK6SCAS1401812-88-1

Targets

O95436SLC34A2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lifastuzumab vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account